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National Healthcare Safety Network (NHSN) Overview
The NHSN is a secure, Internet-based surveillance system that expands and integrates 
patient and healthcare personnel safety surveillance systems managed by the Division of 
Healthcare Quality Promotion at the Centers for Disease Control and Prevention. In 
addition, facilities that participate in certain reporting programs operated by the Centers 
for M edicare and M edicaid Services (CMS) can do so through use o f NHSN. Some U.S. 
states utilize NHSN as a means for healthcare facilities to submit data on healthcare- 
associated infections (HAIs) mandated through their specific state legislation.
NHSN enables healthcare facilities to collect and use data about healthcare-associated 
infections, adherence to clinical practices known to prevent healthcare-associated 
infections, the incidence or prevalence o f multidrug-resistant organisms within their 
organizations, trends and coverage o f healthcare personnel safety and vaccination, and 
adverse events related to the transfusion o f blood and blood products.
The NHSN includes four components: Patient Safety, Healthcare Personnel Safety, 






The Patient Safety Component includes 5 modules that focus on events associated with 
devices, procedures, or antimicrobial agents used during healthcare:
Device-associated Module:
o CLABSI -  Central line-associated bloodstream infection 
o CLIP -  Central line insertion practices adherence 
o CAUTI -  Catheter-associated urinary tract infection 
o VAE -  Ventilator-associated events (>18 year old only) 
o VAP -  Ventilator-associated pneumonia (<18 year old only) 
o DE -  Dialysis Event 
Procedure-associated Module: SSI -  Surgical site infection 
Antimicrobial Use and Resistance Module
Multidrug-Resistant Organism and Clostridium difficile Infection (MDRO/CDI) 
Module
Vaccination Module
Instructions and standardized surveillance methods and definitions for each module o f the 
Patient Safety Component are provided in this manual, except Dialysis Event, and on the 
NHSN website (www.cdc.gov/nhsn) . M odules may be used singly or simultaneously and 
each module has its own minimum time period for required participation (see individual 
protocols for details). Information on Dialysis Event surveillance is provided at 
http://www.cdc.gov/nhsn/psc da de.html.
There are two modules in the Healthcare Personnel Safety (HPS) Component o f NHSN: 
Blood/Body Fluid Exposure Modules W ith or W ithout Exposure M anagement and the 
Influenza Vaccination and Exposure M anagement Modules. These modules may be used 
separately or simultaneously. Instructions and standardized surveillance methods and 
definitions for each module are provided in the NHSN Manual: HPS Component Protocol 
http://www.cdc.gov/nhsn/TOC HPS Manual.html .
The Biovigilance Component o f NHSN was developed in collaboration with the 
transfusion and transplant communities. Biovigilance includes the collection o f adverse 
event data to improve outcomes in the use of blood products, organs, tissues, and cellular 
therapies. The Hemovigilance M odule is the first part o f the Biovigilance Component to 
be developed in NHSN. This module is designed for staff in healthcare facility 
transfusion services to track adverse events, including recipient adverse reactions and 
quality control incidents, related to blood transfusion. Instructions and standardized 




Some o f the options in the following modules require active, patient-based, prospective 
surveillance o f events and their corresponding denominator data by a trained Infection 
Preventionist (IP). This means that the IP shall seek out infections during a patient’s stay 
by screening a variety o f data sources, such as laboratory, pharmacy, 
admission/discharge/transfer, radiology/imaging, and pathology databases, as well as 
patient charts, including history and physical exam notes, nurses/physicians notes, 
temperature charts, etc. Others may be trained to screen data sources for these infections, 
but the IP must make the final determination. Laboratory-based surveillance should not 
be used alone, unless all possible criteria for identifying an infection are solely 
determined by laboratory evidence (e.g., LabID event detection in the M DRO/CDI 
Module). Retrospective chart reviews should be used only when patients are discharged 
before all information can be gathered. NHSN forms should be used to collect all 
required data, using the NHSN definitions o f each data field. To minimize the IP’s data 
collection burden, others may be trained to collect the denominator data and process of 
care data (e.g., central line insertion and inpatient influenza vaccination information).
Procedure-Associated Module
Surgical site infection (SSI) monitoring is offered through a protocol in this module.
This protocol requires active, patient-based, prospective surveillance (see Surveillance 
Techniques above). To minimize IPs’ workload o f collecting denominator data, 
operating room data may be downloaded (see file specifications at: 
http://www.cdc.gov/nhsn/PDFs/ImportingProcedureData current.pdf).
Both post-discharge and ante-discharge surveillance methods should be used to detect 
SSIs following in- and outpatient operative procedures. These methods include 1) direct 
examination o f patients’ wounds during follow-up visits to either surgery clinics or 
physicians’ offices, 2) review o f medical records or surgery clinic patient records, 3) 
surgeon surveys by mail or telephone, and 4) patient surveys by mail or telephone 
(though patients may have a difficult time assessing their infections). Any combination 
o f these methods is acceptable for use; however, CDC criteria for SSI must be used.
Device-Associated Module
Medical instrumentation increases the risk o f development o f an HAI and most patients 
admitted for health care are exposed to some kind o f medical device in the course o f their 
treatment. Such devices include, but are not limited to, venous and urinary catheters, and 
ventilators. NHSN enables facilities to monitor infectious complications associated with 
the use o f these devices and also to monitor processes related to their use which might 
increase infection risk. Specifically, surveillance o f central line-associated bloodstream 
infection (CLABSI), catheter-associated urinary tract infection (CAUTI), ventilator- 
associated events (VAE), and/or ventilator-associated pneumonia (VAP) is possible using
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the NHSN. See Dialysis Event Protocol for detailed instructions for Dialysis Event (DE) 
surveillance (http://www.cdc.gov/nhsn/psc da de.html) . In addition, central line 
insertion practices (CLIP) can be monitored to inform facilities o f the appropriateness of 
their processes and how they may relate to HAI development.
Device-associated denominator data should be collected at the same time each day.
W hen denominator data are available from electronic databases (e.g., ventilator days 
from respiratory therapy), these sources may be used as long as the counts are not 
substantially different (+/- 5%) from manually-collected counts that have been validated 
for a minimum of 3 months.
See the respective device-associated event protocols for detailed surveillance instructions. 
Antimicrobial Use and Resistance (AUR) Module
The use o f antimicrobial agents has a direct effect on antimicrobial resistance patterns o f 
pathogens. The observed increase in multidrug resistance is in part due to inappropriate 
prescription of, as well as incomplete completion of, courses o f antibiotics.
The AUR M odule allows facilities to collect information on the amount o f antimicrobials 
that are utilized for patient care within their systems, as well as to collect data on the 
prevalence o f drug-resistant organisms in their inpatient and outpatient areas. Electronic 
capture o f microbiology and pharmacy data is the available option for this module.
See the Antimicrobial Use and Resistance protocol for detailed surveillance instructions.
M ultidrug-resistant Organism and Clostridium difficile Infection (MDRO/CDI) 
Module
The NHSN M DRO/CDI Module offers a means for facilities to meet criteria and metrics 
that are outlined in several organizational guidelines to control and measure the spread of 
M DROs and CDI within their healthcare system. The module has both required and 
optional surveillance activities that can be tailored to the needs o f the facility. Infection 
surveillance and monitoring o f proxy infection measures are choices available to facilities 
choosing to participate in this program within NHSN.
In addition, process measures related to adherence to contact precautions when caring for 
patients infected or colonized with an MDRO or C. difficile, and/or active surveillance 
testing for such organisms, or outcome measurements o f incidence and prevalence o f 
positive cultures o f these organisms in patients can be undertaken.
See the M DRO/CDI protocol for detailed surveillance instructions.
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Vaccination Module
Influenza continues to be associated with increased morbidity and mortality in certain 
patient populations including the very young, elderly, immunocompromised, and 
pregnant women. Hospitalization has been identified as a potential opportunity to 
provide influenza immunization not only to these at-risk individuals, but also to any 
patient.
The NHSN Vaccination module was not updated for the 2012-2013 influenza season. 
However, the module will be available for use through 2013 as a means for facilities to 
track the success of capitalizing on influenza vaccination opportunities. Two options are 
available related to patient susceptibility and adherence to vaccination recommendations.
See the Vaccination protocol for detailed surveillance instructions.
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